The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

Novartis logo

Novartis

Status and phase

Completed
Phase 4

Conditions

Conduct Disorder

Treatments

Drug: Oxcarbazepine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00154362
CTRI476BES04

Details and patient eligibility

About

Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.

Enrollment

50 patients

Sex

All

Ages

6 to 16 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
  • Score >8 on the Impulsivity Rating Scale

Exclusion criteria

  • Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
  • Treatment with antiepileptic medications

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems